Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the appointment of Marc Malandro, Ph.D., to the company’s scientific advisory board. Dr. Malandro, a highly regarded scientific leader and expert in genomics, molecular biology, biochemistry and bioengineering, will serve alongside other key thought leaders in their respective fields to guide the company’s initiatives and growth strategy. “Marc is not only a very insightful scientist, but he is an equally perceptive and thoughtful innovator. His understanding of the business of science, and the commercial application of novel discovery, is precisely why he is such a valuable scientific advisor,” said Predictive Oncology’s CEO and Board Chairman Raymond F. Vennare. “Marc’s understanding of the depth and breadth of the biopharmaceutical industry is invaluable as we look to build relationships and progress to help accelerate drug discovery and advance drug development.”

To view the full press release, visit https://ibn.fm/Jje9E

About Predictive Oncology Inc.

Predictive Oncology is a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop optimal cancer therapies, which can lead to more effective treatments and improved patient outcomes. Through AI, Predictive Oncology uses a biobank of 150,000+ cancer tumors, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of success. The company offers a suite of solutions for oncology drug development from early discovery to clinical trials. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork